Medtronic has announced a financial investment in Arsenal AAA, a wholly owned subsidiary of Arsenal Medical. In return, Medtronic has received an option to acquire Arsenal AAA after the company achieves certain milestones. Financial terms of the investment were not disclosed.
Arsenal AAA is developing a proprietary foam and delivery mechanism designed to fill the aneurysmal sac around an endograft, thus stabilising the aneurysm and reducing the likelihood of endoleaks. This is especially important in type II endoleaks, where the anatomy of the branch vessels can lead to persistent arterial flow within the aneurysmal sac, even when treated with an endograft. Arsenal AAA’s foam delivery catheter is intended to be used in conjunction with any commercially available endograft and allows for the prophylactic treatment of endoleaks.
“The investment will allow Arsenal AAA to utilise its expertise in foam technologies to address persistent endoleaks that can occur after endovascular aneurysm repair (EVAR) procedures,” said Daveen Chopra, vice president and general manager of the Aortic division, within the Cardiac and Vascular Group (CVG) at Medtronic.
“Medtronic’s strategic investment in Arsenal AAA validates our breakthrough in situ forming foam platform,” said Maria Palasis, chief executive officer of Arsenal Medical. “Medtronic’s leading market position and expertise in this field will help accelerate the introduction of this novel technology to the broader AAA community and we are looking forward to working with such a dynamic company.”